Pharmaceutical Guidelines
Search

FDA Warning Letter to Biotek India (2021)

Last reviewed 19 Oct 2026 · 5 min read

Contents
  1. Letter overview
  2. CGMP findings described by FDA
  3. Finished-product testing before release
  4. Identity testing of incoming components
  5. Stability programme
  6. Product-specific finding: 99% isopropyl rubbing alcohol
  7. FDA’s requested response
  8. What this case illustrates
  9. Frequently asked questions
  10. What did FDA identify as the main CGMP concerns?
  11. Does the warning letter establish the firm’s current compliance status?
  12. What does 21 CFR 211.84(d)(1) require?
  13. See also
  14. References

In short: FDA issued Warning Letter 320-21-45 to Biotek India on 13 May 2021 after reviewing records for its OTC drug products. The letter described concerns with finished-product testing, component identity testing, stability studies and a 99% isopropyl rubbing alcohol product; this summary reports the letter’s dated findings and is not a statement about later compliance status.

Letter overview

The FDA’s Center for Drug Evaluation and Research issued the warning letter to Biotek India on 13 May 2021. It said the agency reviewed records submitted after an April 2020 request and identified CGMP concerns involving drug products intended for the United States. FDA cited 21 CFR Parts 210 and 211 and described three principal testing and control deficiencies. (FDA Warning Letter 320-21-45, Biotek India (13 May 2021))

The sections below paraphrase the agency’s case-specific findings and response requests. FDA’s letter is the primary source for the facts of this case; the eCFR links show the current text of the provisions it cited.

CGMP findings described by FDA

Finished-product testing before release

FDA said the records did not demonstrate adequate testing of finished products before release, including tests for the identity and strength of active ingredients. The agency cited 21 CFR 211.165(a), which requires appropriate laboratory results for each batch against final specifications, including active-ingredient identity and strength, before release. (FDA letter; 21 CFR 211.165(a), current eCFR)

FDA asked the firm to provide its chemical and microbiological release specifications and methods, results for in-date batches distributed to the United States, and an independent assessment of its laboratory system. Those requests applied to this firm’s response to this letter; they are not additional universal test frequencies. (FDA Warning Letter 320-21-45 (2021))

Identity testing of incoming components

FDA said the submitted records did not show that the firm had performed adequate identity testing on incoming components. It cited 21 CFR 211.84(d)(1), which requires at least one identity test for each drug-product component and use of a specific identity test when one exists. (FDA letter; 21 CFR 211.84(d)(1), current eCFR)

The letter requested an independent review of the firm’s material controls, its specifications and testing approach, and its controls for using supplier certificates of analysis. FDA also asked for evidence that the firm’s approach to supplier results was supported by validation and periodic revalidation where applicable. The current provision, 21 CFR 211.84(d)(2), describes when supplier analyses may be used instead of manufacturer testing. (FDA Warning Letter 320-21-45 (2021); 21 CFR 211.84(d)(1)–(2), current eCFR)

Stability programme

FDA said the firm’s stability information did not establish that product quality remained acceptable through the labelled shelf life. The letter noted missing active-ingredient assay results and microbiological stability data, and cited 21 CFR 211.166(a). That provision requires a written stability-testing programme, with results used to establish appropriate storage conditions and expiry dates; it also addresses test methods, storage of samples and testing in the marketed container-closure system. (FDA letter; 21 CFR 211.166(a), current eCFR)

For this firm, FDA requested an independent review and a remediation plan covering stability-indicating methods, studies in marketed packaging, ongoing stability monitoring and defined test attributes at each study interval. These were the agency’s requests in the 2021 letter, not a complete description of every firm’s stability obligations. (FDA Warning Letter 320-21-45 (2021))

Product-specific finding: 99% isopropyl rubbing alcohol

FDA also concluded in this letter that the firm’s 99% isopropyl rubbing alcohol, labelled for first-aid antiseptic use, was an unapproved new drug and was misbranded. FDA’s explanation referred to the product’s failure to meet the conditions it discussed under FD&C Act §505G and to the 1991 tentative final monograph for first-aid antiseptics. The letter described the monograph’s proposed concentration range as 50% to 91.3%, and treated the product’s 99% concentration as outside that proposal. This is a summary of FDA’s 2021 position in this case; it does not present that historical proposal as a universal current limit. (FDA Warning Letter 320-21-45 (2021))

FDA’s requested response

The letter asked the firm to explain its corrections and prevention plan, provide supporting records and timelines, and address affected in-date products. FDA also recommended that the firm use a qualified CGMP consultant to assess the operation and the effectiveness of its corrective actions. The recommendation was directed to this firm in this case; the letter stated that management remained responsible for compliance. (FDA Warning Letter 320-21-45 (2021))

What this case illustrates

The letter shows how FDA connected laboratory controls, component identity testing and stability evidence to decisions about releasing and maintaining drug products. When reviewing a warning letter, distinguish the regulations cited from the additional records and remedial actions requested for that firm. FDA said the listed violations were not intended to be an exhaustive account of every possible deficiency at the facility. (FDA Warning Letter 320-21-45 (2021))

Frequently asked questions

What did FDA identify as the main CGMP concerns?

The letter focused on finished-product testing before release, identity testing of incoming components and the firm’s stability programme. It also discussed a separate concern about the 99% isopropyl rubbing alcohol product. (FDA Warning Letter 320-21-45 (2021))

Does the warning letter establish the firm’s current compliance status?

No. The letter records FDA’s findings and requests as of 13 May 2021. It does not by itself establish what happened after that date.

What does 21 CFR 211.84(d)(1) require?

It requires at least one identity test for each drug-product component and says to use a specific identity test when one exists. (21 CFR 211.84(d)(1), current eCFR)

See also

References

  • U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Biotek India — 613295 — 05/13/2021, Warning Letter 320-21-45 (13 May 2021). Official FDA warning letter.
  • United States. 21 CFR Part 211, current eCFR as accessed 19 October 2026: §211.165(a) (testing and release), §211.84(d)(1)–(2) (component identity testing and supplier results), and §211.166(a) (stability testing). §211.165, §211.84, §211.166.

Related articles